Syndax Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael A. Metzger
- Full Time Employees
- 270
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 35 Gatehouse Drive New York City MA United States of America 02451
- IPO Date
- Mar 2, 2016
- CIK
- 0001395937
- Website
- syndax.com
- Similar Companies
- Business
- Syndax Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical firm dedicated to developing advanced cancer treatments. The company’s portfolio features two key therapeutic candidates that have received FDA approval. Revuforj (revumenib), a selective menin inhibitor, is cleared for relapsed or refractory acute leukemias with KMT2A rearrangements and NPM1 mutations. Concurrently, Niktimvo (axatilimab), a monoclonal antibody that targets the CSF-1 receptor, is approved for treating chronic graft-versus-host disease in patients who have not responded to at least two prior systemic therapies. Both primary compounds are undergoing further clinical investigation for potential expansion into earlier treatment lines, combination regimens, and additional indications such as idiopathic pulmonary fibrosis. Syndax is also advancing Entinostat, a Class 1 HDAC inhibitor, in studies for various solid tumors and specific hematological malignancies. The company maintains strategic alliances, including a global collaboration with Incyte for axatilimab's development and commercialization, alongside other research partnerships. Incorporated in 2005, Syndax Pharmaceuticals is headquartered in Waltham, Massachusetts, concentrating on pioneering therapies to fulfill critical unmet medical requirements.
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Announces Participation in Upcoming Investor Conferences
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
SG Americas Securities LLC Has $2.72 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of “Moderate Buy” by Brokerages
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
Syndax Pharma: Two Drug Launches Fuel Transformational Growth
Apis Capital Advisors LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript